Bafna Pharmaceuticals Ltd

Bafna Pharma. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Bafna Pharmaceuticals Ltd

₹ 89.2 -0.94%
04 Jul - close price
bafnapharma.com BSE: 532989 NSE: BAFNAPH
About

Incorporated in 1981, Bafna Pharmaceuticals
Ltd manufactures finished pharmaceutical formulations[1]

Key Points

Product Profile:[1][2][3]
Company is manufacturing over 336
licensed pharmaceutical formulations
and has globally registered 78 of its
products viz. Afenac-p Tab, Afenac-th
Tab, finished solid oral and liquid oral
dosage forms of Betalactam and Non – Betalactam and Cephalosporin products

Website BSE NSE
  • Market Cap ₹ 210 Cr.
  • Current Price ₹ 89.2
  • High / Low ₹ 96.0 / 67.8
  • Stock P/E
  • Book Value ₹ 216
  • Dividend Yield 0.00 %
  • ROCE -3.00 %
  • ROE -5.36 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Stock is trading at 0.41 times its book value
  • Debtor days have improved from 151 to 51.8 days.

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -15.2% over past five years.
  • Company has a low return on equity of -63.1% over last 3 years.
  • Working capital days have increased from 49.7 days to 90.4 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2018 Sep 2018 Jun 2019 Sep 2019
11.95 8.84 6.85 11.57
13.77 8.66 9.71 11.95
Operating Profit -1.82 0.18 -2.86 -0.38
OPM % -15.23% 2.04% -41.75% -3.28%
0.09 -0.03 0.30 0.59
Interest 0.83 0.62 0.13 0.04
Depreciation 1.00 0.75 1.02 0.72
Profit before tax -3.56 -1.22 -3.71 -0.55
Tax % -1.12% 4.10% -42.59% 7.27%
-3.52 -1.28 -2.13 -0.59
EPS in Rs -1.49 -0.54 -0.90 -2.49
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
129 175 185 97 85 65 46 44 42
110 153 162 114 85 71 81 57 41
Operating Profit 19 22 23 -18 1 -6 -35 -13 1
OPM % 15% 13% 12% -18% 1% -9% -77% -30% 3%
1 3 2 43 2 1 31 1 -22
Interest 8 12 13 13 13 11 7 2 0
Depreciation 6 8 9 6 5 4 4 3 3
Profit before tax 5 5 2 6 -15 -20 -15 -17 -24
Tax % 64% 27% 42% -2% -1% -4% 15% 6% 0%
2 4 1 6 -15 -19 -17 -18 -24
EPS in Rs 1.00 2.12 0.75 3.31 -7.52 -10.23 -7.08 -7.98 -104.54
Dividend Payout % 0% 28% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: -15%
3 Years: -13%
TTM: -3%
Compounded Profit Growth
10 Years: %
5 Years: 14%
3 Years: 24%
TTM: 90%
Stock Price CAGR
10 Years: 13%
5 Years: 32%
3 Years: -8%
1 Year: -3%
Return on Equity
10 Years: %
5 Years: -45%
3 Years: -63%
Last Year: -5%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Equity Capital 18 19 19 19 19 19 24 24 2
Reserves 45 49 50 53 39 24 14 -5 49
85 100 108 69 80 82 47 46 3
70 93 59 59 54 53 54 54 17
Total Liabilities 219 261 236 200 193 178 138 119 71
76 73 69 55 53 49 45 37 35
CWIP 0 0 0 0 0 0 0 0 0
Investments 0 0 0 17 17 17 0 0 0
143 188 167 128 123 113 93 82 36
Total Assets 219 261 236 200 193 178 138 119 71

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
29 37 2 11 1 -1 -7 -2 -34
-38 -6 -7 60 -0 -5 38 15 33
-1 -12 -13 -71 -1 6 -31 -14 7
Net Cash Flow -9 19 -18 -0 -0 -0 0 -0 6

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Debtor Days 237 191 193 335 292 303 195 208 52
Inventory Days 93 63 77 72 90 118 102 122 208
Days Payable 227 223 118 189 208 168 273 519 229
Cash Conversion Cycle 103 30 152 218 174 253 24 -190 31
Working Capital Days 202 151 204 265 300 205 74 -15 90
ROCE % 11% 9% -12% -2% -7% -36% -22% -3%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
90.12% 90.00% 90.01% 89.99% 89.99% 88.73% 88.42% 88.29% 88.29% 88.29% 88.29% 75.00%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8.53%
9.88% 10.00% 9.98% 10.00% 10.00% 11.27% 11.57% 11.70% 11.71% 11.70% 11.70% 16.47%
No. of Shareholders 7,2237,2757,1997,1206,9927,3547,3677,5397,3917,2957,2147,142

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings